共 50 条
- [41] A multicenter, open label, phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Goldinger, Simone M.Gobbi, SharonDing, MichelleFrauchiger, Anna LisaFink-Puches, ReginaKlemke, Claus-DetlevDreno, BrigitteBagot, MartineAssaf, ChalidDummer, Reinhard
- [42] Long-term safety and tolerability of lacosamide monotherapy in patients with epilepsy: Results from a multicenter, open-label trialEPILEPSIA OPEN, 2021, 6 (03) : 618 - 623Ben-Menachem, ElinorDominguez, JacquelineSzasz, JozsefBeller, CynthiaHowerton, CharlesJensen, LoriMcClung, CarrieRoebling, RobertSteiniger-Brach, Bjorn
- [43] TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive gliomaNEURO-ONCOLOGY ADVANCES, 2024, 6 (01)Picca, AlbertoDi Stefano, Anna LuisaSavatovsky, JulienDucray, FrancoisChinot, OlivierMoyal, Elisabeth Cohen-JonathanAugereau, PauleLe Rhun, EmilieSchmitt, YohannRousseaux, NabilaYepnang, Ariane Murielle MbekweEstellat, CandiceCharbonneau, FrederiqueLetourneur, QuentinBranger, Dominique FigarellaMeyronet, DavidFardeau, ChristineMokhtari, KarimaBielle, FranckIavarone, AntonioSanson, Marc
- [44] Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trialHAEMATOLOGICA, 2025, 110 (03) : 683 - 692Lin, NingjingSun, XiuhuaZhou, HuiZou, LiqunZhou, KeshuLiu, LihongYang, HaiyanHu, KaiCai, QingqingLiu, YaoJin, JieZhang, LilingLi, WenyuGuo, YeYang, WeiLuo, FengWang, ZhenguangZhu, RongYang, LeiSong, DanSong, YuqinZhu, Jun
- [45] Phase II Multicenter Study of the Safety and Efficacy of Single-Agent Lenalidomide in Subjects with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Follow-up Analysis of the NHL-003 StudyBLOOD, 2012, 120 (21)Zinzani, Pier LuigiVose, Julie M.Czuczman, Myron S.Reeder, CraigHaioun, CorinnePolikoff, JonathanTilly, HervePietronigro, DennisErvin-Haynes, AnnetteLi, JuWitzig, Thomas E.
- [46] An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophreniaChild and Adolescent Psychiatry and Mental Health, 6 (1)Gahan PandinaStuart KushnerKeith KarcherMagali Haas
- [47] An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumorsANTI-CANCER DRUGS, 2007, 18 (03) : 273 - 276Oechsle, KarinHonecker, FriedemannKollmannsberger, ChristianRick, OliverGruenwald, VictorMayer, FrankHartmann, Joerg T.Bokemeyer, Carsten
- [48] Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 studyJOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)Huang, HuiqiangZhu, JunYao, MingKim, Tae MinYoon, Dok HyunCho, Seok-GooEom, Hyeon SeokLim, Soon ThyeYeh, Su-pengSong, YuqinKwong, Yok LamKim, Jin SeokJin, JieShi, YuankaiKim, HyeJinQing, MinZhou, TianyuanGao, GraceDong, ZongqiQi, MingKim, Won Seog
- [49] Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 studyJournal of Hematology & Oncology, 14Huiqiang HuangJun ZhuMing YaoTae Min KimDok Hyun YoonSeok-Goo ChoHyeon Seok EomSoon Thye LimSu-peng YehYuqin SongYok Lam KwongJin Seok KimJie JinYuankai ShiHyeJin KimMin QingTianyuan ZhouGrace GaoZongqi DongMing QiWon Seog Kim
- [50] SAFETY, EFFICACY, AND PHARMACOKINETICS OF INTRAVENOUS RIGOSERTIB IN JAPANESE PATIENTS WITH RECURRENT/RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES: A MULTICENTER, OPEN-LABEL, PHASE I STUDYHAEMATOLOGICA, 2017, 102 : 766 - 766Ogura, M.Kobayashi, Y.Kubonishi, S.Hidaka, M.Uchida, T.Takamatsu, Y.